R
Roxana Mehran
Researcher at Icahn School of Medicine at Mount Sinai
Publications - 1584
Citations - 115692
Roxana Mehran is an academic researcher from Icahn School of Medicine at Mount Sinai. The author has contributed to research in topics: Percutaneous coronary intervention & Myocardial infarction. The author has an hindex of 141, co-authored 1378 publications receiving 99398 citations. Previous affiliations of Roxana Mehran include Yale University & Mount Sinai Hospital.
Papers
More filters
Journal ArticleDOI
Clinical End Points in Coronary Stent Trials A Case for Standardized Definitions
Donald E. Cutlip,Stephan Windecker,Roxana Mehran,Ashley B Boam,David J. Cohen,Gerrit-Anne van Es,P. Gabriel Steg,Marie-Angèle Morel,Laura Mauri,Pascal Vranckx,Eugene P. McFadden,Alexandra J. Lansky,Martial Hamon,Mitchell W. Krucoff,Patrick W. Serruys +14 more
TL;DR: Criteria for assessment of death, myocardial infarction, repeat revascularization, and stent thrombosis were developed and provide consistency across studies that can facilitate the evaluation of safety and effectiveness of these devices.
Journal ArticleDOI
Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document.
A. Pieter Kappetein,Stuart J. Head,Philippe Généreux,Nicolo Piazza,Nicolas M. Van Mieghem,Eugene H. Blackstone,Thomas G. Brott,David J. Cohen,Donald E. Cutlip,Gerrit Anne van Es,Rebecca T. Hahn,Ajay J. Kirtane,Mitchell W. Krucoff,Susheel Kodali,Michael J. Mack,Roxana Mehran,Josep Rodés-Cabau,Pascal Vranckx,John G. Webb,Stephan Windecker,Patrick W. Serruys,Martin B. Leon +21 more
TL;DR: This VARC-2 document has provided further standardization of endpoint definitions for studies evaluating the use of TAVI, which will lead to improved comparability and interpretability of the study results, supplying an increasingly growing body of evidence with respect to TAVi and/or surgical aortic valve replacement.
Journal ArticleDOI
Standardized Bleeding Definitions for Cardiovascular Clinical Trials A Consensus Report From the Bleeding Academic Research Consortium
Roxana Mehran,Sunil V. Rao,Deepak L. Bhatt,C. Michael Gibson,Adriano Caixeta,John W. Eikelboom,Sanjay Kaul,Stephen D. Wiviott,Venu Menon,Eugenia Nikolsky,Victor L. Serebruany,Marco Valgimigli,Pascal Vranckx,David P. Taggart,Joseph F. Sabik,Donald E. Cutlip,Mitchell W. Krucoff,E. Magnus Ohman,Philippe Gabriel Steg,Harvey D. White +19 more
TL;DR: Bleeding complications have been associated with an increased risk of subsequent adverse outcomes, including MI, stroke, stent thrombosis, and death, in patients with ACS and in those undergoing percutaneous coronary intervention (PCI) as well as in the long-term antithrombotic setting.
Journal ArticleDOI
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions
Glenn N. Levine,Eric R. Bates,James C. Blankenship,Steven R. Bailey,John A. Bittl,Bojan Cercek,Charles E. Chambers,Stephen G. Ellis,Robert A. Guyton,Steven M. Hollenberg,Umesh N. Khot,Richard A. Lange,Laura Mauri,Roxana Mehran,Issam Moussa,Debabrata Mukherjee,Brahmajee K. Nallamothu,Henry H. Ting,Alice K. Jacobs,Nancy M. Albert,Mark A. Creager,Steven M. Ettinger,Jonathan L. Halperin,Judith S. Hochman,Frederick G. Kushner,E. Magnus Ohman,William G. Stevenson,Clyde W. Yancy +27 more
TL;DR: Alice K. Jacobs, MD, FACC, FAHA, Chair Jeffrey L. Anderson, PhD, CCNS, CCRN, FAH, Chair-Elect - The first female FACC-FAHA board member to be elected in the history of the sport.
Journal ArticleDOI
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II.
Morteza Naghavi,Peter Libby,Erling Falk,S. Ward Casscells,S. Ward Casscells,Silvio H. Litovsky,Silvio H. Litovsky,John A. Rumberger,Juan J. Badimon,Christodoulos Stefanadis,Pedro R. Moreno,Gerard Pasterkamp,Zahi A. Fayad,Peter Stone,Sergio Waxman,Paolo Raggi,Mohammad Madjid,Mohammad Madjid,Alireza Zarrabi,Alireza Zarrabi,Allen P. Burke,Chun Yuan,Peter J. Fitzgerald,David S. Siscovick,Chris L. de Korte,Masanori Aikawa,K.E. Juhani Airaksinen,Gerd Assmann,Christoph R. Becker,James H. Chesebro,Andrew Farb,Zorina S. Galis,Christopher L. Jackson,Ik-Kyung Jang,Wolfgang Koenig,Robert A. Lodder,Keith L. March,Jasenka Demirovic,Mohamad Navab,Silvia G. Priori,Mark D. Rekhter,Raymond D. Bahr,Scott M. Grundy,Roxana Mehran,Antonio Colombo,Eric Boerwinkle,Christie M. Ballantyne,William Insull,Robert S. Schwartz,Robert A. Vogel,Patrick W. Serruys,Göran K. Hansson,David P. Faxon,Sanjay Kaul,Helmut Drexler,Philip Greenland,James E. Muller,Renu Virmani,Renu Virmani,Paul M. Ridker,Douglas P. Zipes,Prediman K. Shah,James T. Willerson,James T. Willerson +63 more
TL;DR: The term "vulnerable patient" may be more appropriate and is proposed now for the identification of subjects with high likelihood of developing cardiac events in the near future and a quantitative method for cumulative risk assessment of vulnerable patients needs to be developed.